Sofpironium is a topical anticholinergic used to treat primary axillary hyperhidrosis. Sofpironium is a "soft" anticholinergic analog of glycopyrronium that has been modified with a readily hydrolyzable ester moiety.
- Mechanism
- Curator reviewed · 1 reference
Sofpironium is a competitive inhibitor of muscarinic acetylcholine receptors are located on certain peripheral tissues, including eccrine sweat glands. By inhibiting the activity of these receptors, sofpironium indirectly reduces the rate of sweating in patients with axillary hyperhidrosis.
- Primary indication
- Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis in patients ≥9 years of age.Curator reviewed · 1 structured indication
- Formula / weight
- C22H32NO5 · 390.499 g/mol (avg)
- First approval
- United States, 2024
- Also known as
- Pyrrolidinium, 3-(((2r)-2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy)-1-(2-ethoxy-2-oxoethyl)-1-methyl-, (3r)- · Sofpironium cation · Sofpironium ion
- Code names
- BBI-4000 cation · BBI-4000 ion
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
SEVCTUCCZYBJER-BSJAROSPSA-NSMILESCCOC(=O)C[N+]1(C)CC[C@H](C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1Targets
Transporters
What you can answer from here — as of August 31, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
3TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Sofpironium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account